Together, our results support further investigation of extracellular administration of rA6 as a potential novel therapeutic approach to limit Aβ-induced membrane damage for the prevention of dystrophic neurites in AD, which could have beneficial effects on tau pathology. Here, MAPT is linked to Alzheimer disease.